Valganciclovir (VGCV) followed by cytomegalovirus (CMV) hyperimmune globulin compared to VGCV for 200days in abdominal organ transplant recipients at high risk for CMV infection: A prospective, randomized pilot study.

Abstract

With the advent of effective antivirals against cytomegalovirus (CMV), use of CMV hyperimmune globulin (HIG) has decreased. Although antiviral prophylaxis in patients at high risk for CMV is effective, many patients still have late infection, never developing antibodies sufficient to achieve immunity. Utilizing a combination of antiviral and CMV HIG may allow patients to achieve immunity and decrease late CMV infections. This was a prospective randomized, open-label, pilot study comparing valganciclovir (VGCV) prophylaxis for 200days vs VGCV for 100days followed by CMV HIG in abdominal transplant recipients at high risk for CMV. The primary outcome was a comparison of late CMV disease. Forty patients were randomized to VGCV for 200days (n=20) or VGCV for 100days followed by 3 doses of monthly CMV HIG (n=20). Numerically, more overall CMV infections occurred in the CMV HIG group (45 vs 20%, P=.09). No differences in overall CMV infections or late CMV disease were seen between groups (20% vs 15%, P=1.00 and 0 vs 0, P=1.00). All CMV disease occurred within 200days, with 63% occurring while patients were on VGCV. No differences were found in toxicities, graft function, or rejection between groups. Patients with CMV infection at any time had a higher body weight than those who did not have an infection (82 vs 95kg, P=.049). Use of CMV HIG sequentially with prophylaxis may be an effective and affordable prophylactic regimen in abdominal transplant recipients at high risk for CMV, and warrants larger prospective study. Increased monitoring for patients with obesity may be warranted.